Data from 7 UK NHS centres 1
This retrospective study investigated the impact of rifaximin-α for secondary prevention of OHE on hospital resource utilisation using real world data from 7 UK centres.
1
Mean annual hospital length of stay per patient
Adapted from Orr et al. 2016
- Absolute reduction 12.9 days/person/year
- Relative reduction 52.7%, p<0.001
Mean annual length of stay per patient reduced from 24.4 days before to 11.5 days during rifaximin-α treatment
1
- Absolute reduction 4.9 days/admission
- Relative reduction 36.3%, p=0.017
Mean hospital length of stay per admission decreased from 13.5 days/admission before to 8.6 days/admission during rifaximin-α treatment
1
Mean hospital length of stay per admission
Adapted from Orr et al. 2016
Data from the IMPRESS study 2,3
A retrospective, observational, multicentre study including 145 patients with HE from 11 UK NHS centres. Conducted from Aug 2014 to Jun 2015.
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
This study was sponsored by Norgine.
AIM: To compare resource use in the 6 and 12 months before and after rifaximin-α initiation in UK patients with HE.
This study was sponsored by Norgine.
Total number of hospital bed days
2
All-cause admissions
Safety
- 4% patients (9/145) reported adverse drug reactions(ADRs)
- 4/9 of these patients had C difficile infection and none discontinued treatment
- No serious ADRs were reported
UK/XIF5/0719/0523 DOP: October 2019